Inhibikase Therapeutics (IKT) risk factors, FY2024 10-K

Other

1. 01Our business is subject to numerous risks and uncertainties that you should consider before investing in our Company

Risks Related to Our Business, Financial Condition and Capital Requirements

1. 02We are a clinical-stage drug development company with limited resources, a limited operating history and have no products approved for commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability
2. 03If we are unable to successfully raise additional capital, our future clinical trials and product development could be limited and our long-term viability may be threatened
3. 04We may not be able to acquire additional funds on acceptable terms, or at all. If we are unable to raise adequate funds, we may have to liquidate some or all of our assets or delay, reduce the scope of or eliminate some or all of our development programs
4. 05Drug development is a highly uncertain undertaking and involves a substantial degree of risk. We have never generated any revenue from product sales, we may never generate any revenue from product sales, and we may fail to generate further revenue from grants or contracts or to be profitable
5. 06attracting, hiring and retaining qualified personnel
6. 07Adverse developments affecting financial institutions, companies in the financial services industry or the financial services industry generally, including those we do business with, could adversely affect our operations and liquidity
7. 08new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business
8. 09Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints
9. 10We have incurred net losses since our inception, including net losses of $27,519,886 and $19,028,883 for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $94,420,611
10. 11defend against any product liability claims or other lawsuits related to our products
11. 12If we fail to obtain additional financing, we may be unable to complete the development of and, if approved, commercialization of our product candidates

Risks Related to the Discovery, Development and Commercialization of Our Product Candidates

1. 13If any of these events occur, we may be forced to abandon our development efforts for a program or programs, which could have a material adverse effect on our business and could potentially cause us to cease operations
2. 14We may seek approval of our product candidates into FDA’s Real-Time Oncology Review (“RTOR”) program. This program may not lead to a faster regulatory review or approval process and does not increase the likelihood that our product candidate(s) will receive marketing approval
3. 15We have limited experience with conducting clinical trials for novel drug substances and no history of commercializing pharmaceutical products, which may make it difficult to evaluate the prospects for our future viability
4. 16Our clinical trials may reveal significant adverse events, toxicities or other side effects not seen in our preclinical studies and may result in a safety profile that could inhibit regulatory approval or market acceptance of any of our product candidates
5. 17communication plan for healthcare providers, and/or other elements to assure safe use. Any of these developments could materially harm our business, financial condition and prospects
6. 18We may not be successful in our efforts to continue to create a pipeline of product candidates or to develop commercially successful products. If we fail to successfully identify and develop additional product candidates, our commercial opportunity may be limited
7. 19We have concentrated much of our research and development efforts on the treatment of neurodegenerative diseases, a field that has seen limited success in drug development
8. 20We may encounter substantial delays in our current and planned clinical trials, or may not be able to conduct or complete our clinical trials on the timelines we expect, if at all
9. 21delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical trials or the inability to do any of the foregoing
10. 22We may encounter difficulties enrolling patients in our current and planned clinical trials, and our clinical development activities could thereby be delayed or otherwise adversely affected
11. 23Our current and planned clinical trials may fail to demonstrate substantial evidence of the safety and efficacy of our product candidates, which would prevent, delay or limit the scope of regulatory approval and commercialization
12. 24Clinical development is a lengthy and expensive process with an uncertain outcome, and failure can occur at any stage of clinical development. If we are unable to design, conduct and complete our current and planned clinical trials successfully, our product candidates will not be able to receive regulatory approval
13. 25Any of these delays or additional requirements could cause our product candidates to not be approved, or if approved, significantly impact the timing and commercialization of our product candidates and significantly increase our overall costs of drug development
14. 26If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved
15. 27unforeseen costs and expenses associated with creating an independent commercialization organization
16. 28Even if any product candidates we develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success
17. 29the prevalence and severity of any side effects
18. 30Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business
19. 31If any of our product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such drugs, which may result in a material decline in sales of affected products
20. 32a decline in the price of our Common Stock

Risks Related to Regulatory Approval and Other Legal Compliance Matters

1. 33the approval policies or regulations of the FDA, EMA or comparable foreign regulatory authorities may significantly change in a manner rendering our preclinical or clinical data insufficient for approval
2. 34This lengthy approval process, as well as the unpredictability of the results of clinical trials, may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations, and prospects
3. 35approval, but there is no guarantee that Review Team interactions will ultimately lead to the approval of IKT-001 or any other product candidates we may develop
4. 36If we file a Section 505(b)(2) application that references a product marketed by another manufacturer, we may be subject to a patent infringement suit and the approval of our product may be delayed
5. 37We may conduct future clinical trials for our product candidates outside the United States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials
6. 38Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions
7. 39Even if we obtain regulatory approval for a product candidate, our products will remain subject to extensive regulatory scrutiny
8. 40clinical trial to confirm clinical benefit for our products. An unsuccessful post-marketing study or failure to complete such a study could result in the withdrawal of marketing approval
9. 41require a product recall
10. 42If, in the future, we seek a breakthrough therapy designation by the FDA for our product candidates, we might not receive such designation, and even if we do, such designation may not lead to a faster development of any product candidate or approval process for any product candidate
11. 43Healthcare legislative measures aimed at reducing healthcare costs may have a material adverse effect on our business and results of operations
12. 44Our employees, independent contractors, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements
13. 45report financial information or data accurately or to disclose unauthorized activities to us
14. 46If we fail to comply with healthcare laws, we could face substantial penalties and our business, operations and financial conditions could be adversely affected
15. 47If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business
16. 48Data collection is governed by restrictive regulations governing the use, processing and cross-border transfer of personal information

Risks Related to Our Reliance on Third Parties

1. 49delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our product candidates. As a result, the commercial prospects for our product candidates would be harmed, our costs could increase substantially and our ability to generate revenue could be delayed
2. 50We expect to depend in whole or in part on collaborations with third parties for the research, development and commercialization of any product candidates we may develop. If any such collaborations are not successful, we may not be able to realize the market potential of those product candidates
3. 51the inability to produce required volume in a timely manner and to quality standards
4. 52Any product candidates that we may develop may compete with other product candidates and products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us
5. 53Manufacturing issues may arise that could increase product and regulatory approval costs or delay commercialization
6. 54We depend on third-party suppliers for key raw materials used in the manufacturing processes for our product candidates, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business
7. 55We currently rely on a small number of suppliers for manufacturing our product candidates
8. 56We are dependent on third-party manufacturers which are located in China, and any inability to obtain products from any such manufacturers could harm our business

Risks Related to Our Intellectual Property

1. 57If any of our owned patent applications do not issue as patents in any jurisdiction, we may not be able to compete effectively
2. 58If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical technology and product candidates would be adversely affected
3. 59result in substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us
4. 60If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business
5. 61the priority of invention of patented technology
6. 62We may not be able to protect our intellectual property and proprietary rights throughout the world
7. 63Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
8. 64Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products
9. 65Issued patents covering our product candidates and other technologies could be found invalid or unenforceable if challenged in court or before administrative bodies in the United States or abroad
10. 66If we do not obtain patent term extension and data exclusivity for any product candidates we may develop, our business may be materially harmed
11. 67We may be subject to claims challenging the inventorship of our patents and other intellectual property
12. 68If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
13. 69We may be subject to claims that our employees, consultants, or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property
14. 70Third-party claims of intellectual property infringement, misappropriation or other violation against us, our licensors or our collaborators may prevent or delay the development and commercialization of our product candidates and other technologies
15. 71We may become involved in lawsuits to protect or enforce our patents and other intellectual property rights, which could be expensive, time consuming, and unsuccessful
16. 72If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
17. 73Intellectual property rights do not necessarily address all potential threats
18. 74Should any of these events occur, they could have a material adverse effect on our business, prospects, financial condition and results of operations

Risks Related to Our Operations

1. 75We will need to grow the size and capabilities of our organization, and we may experience difficulties in managing this growth
2. 76As of the date of this Annual Report, we had fifteen full-time employees and one part-time employee. Due to our limited employee headcount and dependence on contractors, we have operated with our employees and contractors conducting most of their activities outside of our offices
3. 77managing increasing operational and managerial complexity
4. 78We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy
5. 79Cybersecurity breaches could expose us to liability, damage our reputation, compromise our confidential information or otherwise adversely affect our business
6. 80Our computer systems, or those used by our third-party research institution collaborators, CROs or other contractors or consultants, may fail or suffer security breaches
7. 81Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
8. 82Our ability to use our net operating loss carry forwards and certain other tax attributes may be limited
9. 83Geopolitical instability and ongoing military conflicts, including the conflict between Russia and Ukraine and the conflict between Israel and Hamas could materially adversely affect our business, results of operations, and financial condition
10. 84Our results of operations have been adversely affected and, in the future, could be materially adversely impacted by future epidemics and pandemics

Risks Related to Ownership of Our Common Stock

1. 85The market price of our common stock may be volatile
2. 86general economic, industry, and market conditions
3. 87Commencing December 31, 2025, we will no longer qualify as an “emerging growth company” as defined in the JOBS Act, and the reduced disclosure requirements applicable to emerging growth companies will no longer apply to us
4. 88on our Common Stock) or a public float (based on our Common Stock) that is less than $700 million, annual revenues of $100 million or more during the most recently completed fiscal year
5. 89We will continue to incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives and corporate governance practices
6. 90We do not expect to pay any dividends for the foreseeable future. Investors in our common stock may never obtain a return on their investment
7. 91Delaware law and provisions in our amended and restated certificate of incorporation and bylaws might discourage, delay, or prevent a change in control of our company or changes in our management and, therefore, depress the trading price of our common stock
8. 92require the affirmative vote of at least 66 2/3% or more of the outstanding shares of common stock to amend many of the provisions described above
9. 93The choice of the Court of Chancery of the State of Delaware as the sole and exclusive forum for any derivative action or proceeding brought on behalf of us shall not apply to suits seeking to enforce a duty or liability created by the Securities Act or the Exchange Act
10. 94Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
11. 95the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met
12. 96If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline
13. 97Changes in U.S. tax law could adversely affect our business and financial condition
14. 98If we engage in acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks
15. 99our inability to generate revenue from acquired intellectual property, technology and/or products sufficient to meet our objectives or even to offset the associated transaction and maintenance costs
16. 100Our business activities may be subject to the Foreign Corrupt Practices Act (“FCPA”), and similar anti-bribery and anti-corruption laws
17. 101Our business is subject to economic, political, regulatory and other risks associated with conducting business internationally
18. 102business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods, fire, epidemics and pandemics